Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sol-Gel announces positive results from E-BPO phase II study
The drug developed by Sol-Gel, is used to treat mild-to-severe rosacea as well as acne. The study demonstrated that 5% E-BPO provides a safe and effective treatment for
The drug developed by Sol-Gel, is used to treat mild-to-severe rosacea as well as acne. The study demonstrated that 5% E-BPO provides a safe and effective treatment for
I-Accountability decreases workload at the site by centralising and automating the drug accountability process as well as improving compliance and advancing study timelines. The system also features QR
A supplemental biologics license application (sBLA) was submitted to the FDA and a Type II Variation to the European Medicines Agency requesting clearance for Stelara (ustekinumab). The applications
According to the clinical development agreement, Protalix will continue to manage and fund Elelyso (taliglucerase alfa) ongoing trials while the new studies of the enzyme replacement therapy will
The companies are also considering signing a licensing contract to develop new DuoBody product. Genmab’s DuoBody platform swiftly generates bispecific antibodies through a process performed at standard bench,
Health Canada has also started enquiring the company’s customers regarding the ways and means used by it in testing a product. According to Health Canada’s enquiry, the company
The Patent No. 8,324,266 covers methods for treating pulmonary disease using Pearl’s co-suspension technology in metered-dose inhalers (MDIs). The technology is used in PT003, a fixed dose combination
In exchange, uniQure granted Benitec a non-exclusive access to its AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B. Benitec’s ddRNAi technology has the
The CNS Black supplement can be used by elite athlete or people who deal with a lot of stress and daily pressure. Containing a naturally non-essential amino acid,
Cenduit chief executive officer Jogin Desai said clinical trials are complex than ever and a reliable clinical trial supply strategy is important to study success. "The simulation and